Table 2. Antitumor Activity of Cabozantinib.
| Measurement | Cohort A (n = 33)a | Cohort B (n = 55)b |
|---|---|---|
| Best intracranial response, No. (%)c | ||
| Complete response | 3 (10) | 1 (2) |
| Partial response | 14 (45) | 24 (45) |
| Stable disease | 10 (32) | 22 (42) |
| Progressive disease | 4 (13) | 6 (11) |
| Response rate, % (95% CI) | ||
| Intracranial | 55 (36-73) | 47 (33-61) |
| Extracranial | 48 (31-66) | 38 (25-52) |
| Outcome, % (95% CI), mo | ||
| TTF | 8.9 (5.9-12.3) | 9.7 (6.0-13.2) |
| OS | 15.0 (9.0-30.0) | 16.0 (12.0-21.9) |
Abbreviations: OS, overall survival; TTF, time to treatment failure.
Evidence of radiological intracranial progressive disease at baseline (prior brain-directed local therapy was allowed if radiological confirmation of intracranial progression was demonstrated before starting cabozantinib).
Patients with stable brain metastases at cabozantinib initiation or patients with progressing brain metastases concomitantly treated by brain-directed local therapy. Concomitant brain-directed local therapy was defined as any brain-directed local therapy within 2 months prior to cabozantinib initiation.
A total of 84 patients were included (31 in cohort A and 53 in cohort B) for intracranial response analysis, excluding 4 patients whose intracranial treatment response was not evaluable owing to lesion size less than 5 mm.